Topamax, along with several other medications, including Naltrexone, Campral, Baclofen and Acomplia, have provided much-needed relief for problem drinkers and early-stage alcoholics
Anchorage, AK (PRWEB) October 11, 2007
In a study published this week in the Journal of the American Medical Association, researchers reported a 15 percent increase in alcohol abstinence for individuals prescribed a drug commonly known as Topamax compared to those taking a placebo. Yet FDA approval might take years.
When the study began, 371 participants, each heavy drinkers, consumed 11 alcoholic beverages per day on average. Volunteers were encouraged to stop drinking, though never required. Half of the participants were prescribed gradually increasing doses of Topamax while the other half received a placebo. At the study's conclusion, 15 percent of those receiving Topamax, as opposed to just three percent of those receiving a placebo, had quit drinking altogether for seven weeks or more.
"Topamax, along with several other medications, including Naltrexone, Campral, Baclofen and Acomplia, have provided much-needed relief for problem drinkers and early-stage alcoholics," states Roberta Jewell, author of the book My Way Out and owner of the highest trafficked alternative recovery website on the Internet, MyWayOut.org (stats courtesy Alexa.com).
"The My Way Out program incorporated Topamax two years ago as part of a popular, multi-faceted treatment plan," says Jewell. "It combines vitamins, minerals, amino acid and herb therapy formulated specifically to address detoxification, craving and dependence along with home-based hypnotherapy sessions, light exercise and Topamax or other anti-craving drug administration."
The latest research further reinforces the findings in the report "Oral topiramate for treatment of alcohol dependence: a randomized controlled trial" conducted by Bankole A. Johnson et al and published in The Lancet on May 17, 2003. Dr. Johnson's study found that up to 300 mg of Topamax per day was more effective than a placebo as an adjunct to standardized medication compliance management in the treatment of alcohol dependence. Johnson has expressed support for the My Way Out program when administered in conjunction with professional medical guidance and supervision.
To learn more about My Way Out, visit MyWayOut.org.
About My Way Out
My Way Out, Patent Pending, was founded in 2003 by Roberta Jewell, a pen name, to provide a multi-faceted solution for the control of early-stage alcoholism and problem drinking. The program is considered an alternative or supplemental approach to Alcoholics Anonymous and other 12-step programs. Contrary to these programs, My Way Out is administered in a private environment.